Loading, please wait ...


News Analytics

890f36dcbd8593b65845fb377d17c767588ecdac 660x363 jpg?fit=crop&auto=format.
The FDA has approved the VENTANA ALK (D5F3) CDx assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer (NSCLC) who are eligible to receive treatment with lorlatinib (Lorbrena).1 On March 3, 2021, the FDA gave the green light to expand the indication of lorlatinib to include use in the frontline treatment of patients with ALK-positive ...
Google

Subject Matter

  • Healthcare 57.58%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 42.42%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions